IGF-1 receptor binding
IGF-1 LR3 activates the IGF-1 receptor and downstream kinase signalling.
NXP / 09
Research profile
IGF-1 LR3
1MGLong-acting IGF-1 analogue research material
IGF-1 LR3 is an engineered analogue of insulin-like growth factor 1 with an Arg3 substitution and an extended amino-terminal sequence. It is used in controlled research on IGF-1 receptor signalling and reduced binding-protein affinity.
NEXPEP PRICE$109.00 AUDThe same current price shown throughout the Nexpep store.
Scientific context
What it does.
Research applications examine IGF-1 receptor activation, cell proliferation, survival signalling and metabolic responses. Results are highly dependent on cell type, nutrient state, concentration and exposure duration.
Mechanism map
How the research
model works.
Reduced binding-protein affinity
Its sequence modifications reduce affinity for several IGF-binding proteins compared with native IGF-1.
Context-dependent response
Downstream growth and metabolic signals depend on model conditions and available substrates.
Study design
Research pairing
options.
These are experimental design concepts—not recommendations for human use, co-administration or dosing.
Native IGF-1 comparator
Allows direct comparison of receptor signalling and binding-protein effects.
Match molar exposure rather than vial mass alone.Vehicle control
Provides a baseline for proliferation and survival assays.
Use identical media, timing and handling.Unstacked control
A single-agent arm avoids confounding endocrine and mitogenic signals.
Predefine stopping criteria for high-response cell models.Interpretation controls
Important
limitations.
- IGF-1 LR3 is not represented as an approved medicine or for human use.
- Mitogenic assays require appropriate containment, dose-response controls and model-specific safety review.
- Do not extrapolate animal or cell-culture results directly to human outcomes.
Evidence trail